Creating teams. Shaping futures.

Back to headlines

Product | People | Potential – our chat with MeOmics Technology Ltd.

We caught up with Alasdair Pettigrew, CEO at MeOmics, the global provider in Precision Psychiatry.

The purpose of article series ‘Product | People | Potential’ is to feature and showcase the very best UK start-ups with great potential, truly inspiring businesses that are shaking up their sector. We capture and share the stories behind the name. We collate authentic peer to peer real-talk, while celebrating the growth and success thus far and gather a glimpse of what’s ahead.

Jazz @ADLIB: Can you please introduce MeOmics, what MeOmics does, what stage you are at currently and what makes your business and offering unique?

Alasdair Pettigrew: I’m Alasdair, I work for MeOmics, which has created the only platform for neural biomarker discovery for psychiatric disorders. We have developed a unique genetic and stem cell technology to capture and combine patient data to create a Precision Psychiatry Platform. Initially, this technology will be offered as a screening service to pharmaceutical companies to improve drug discovery for psychiatric disorders. Ultimately our vision is to transform mental healthcare through better biological measures. Personalising mental healthcare, to enable getting the right therapy to patients more quickly for better outcomes. We are initially focusing on Schizophrenia, but this has the potential to be expanded for use in a range of neurological disorders, such as bipolar disorder and autism.

We hope to make a difference in a field of medicine which has been under-innovated in previously, we are trying to achieve a biological measure, an objective, consistent measure of psychiatric disorders. Feedback from psychiatrists suggests that they would love to have a screening test which indicates successful drugs for patients, which is a longer term vision for MeOmics. Initially, we are trying to provide information for drug companies who are going into Phase III Clinical Trials by reducing the drug failure rate, and therefore reducing costs, and risk.

Jazz @ADLIB: Can you share the story behind the origin of MeOmics?

Alasdair Pettigrew: MeOmics is a spinout from Cardiff University, founded by two senior Professors, Adrian Harwood and Jeremy Hall, with support from other talented scientists and special